Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries.
about
Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories.Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus.Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine.Considerations for the rapid deployment of vaccines against H7N9 influenza.Live Attenuated Influenza H7N3 Vaccine is Safe, Immunogenic and Confers Protection in Animal Models.H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers.Market implementation of the MVA platform for pre-pandemic and pandemic influenza vaccines: A quantitative key opinion leader analysis.Safety, immunogenicity and infectivity of new live attenuated influenza vaccines.Refining the approach to vaccines against influenza A viruses with pandemic potential.H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial.Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.Immunogenicity and Cross Protection in Mice Afforded by Pandemic H1N1 Live Attenuated Influenza Vaccine Containing Wild-Type Nucleoprotein.PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries.Rapid strategy for screening by pyrosequencing of influenza virus reassortants--candidates for live attenuated vaccinesGeneration and Characterization of Live Attenuated Influenza A(H7N9) Candidate Vaccine Virus Based on Russian Donor of Attenuation.Development of one-step real-time PCR assay for titrating trivalent live attenuated influenza vaccines.Application of real time RT-PCR for the genetic homogeneity and stability tests of the seed candidates for live attenuated influenza vaccine production.Implementation of new approaches for generating conventional reassortants for live attenuated influenza vaccine based on Russian master donor viruses.Evasion of influenza A viruses from innate and adaptive immune responses.Genotyping assay for differentiation of wild-type and vaccine viruses in subjects immunized with live attenuated influenza vaccine.Development of a stable liquid formulation of live attenuated influenza vaccine.Safety of Russian-Backbone Trivalent, Live Attenuated Seasonal Influenza Vaccine in Healthy Subjects: Open-Label, Non-randomized Phase 4 Study.IRES-based co-expression of influenza virus conserved genes can promote synergistic antiviral effects both in vitro and in vivo.
P2860
Q30151807-B752FE2D-5055-4581-98C2-08710655DF24Q30205252-ADE36E0A-720C-4FD6-8868-FA2D521B3A4CQ30359013-2BB7C541-8473-4A60-83B0-3A85566727FCQ30364635-7BB9376E-A8EE-47EC-9AAB-55076BA2A2D0Q30371798-E4BBC22E-90AA-4D3E-8370-E9C05083C512Q30373298-B37E8813-D23D-4E79-B07B-4E7C5BDCCC01Q30375380-71940770-B3A0-47F3-8E3E-11563F00D25BQ30378132-9C7FE145-D046-451E-841C-A6A909D5BAF0Q30381595-679F7D61-9934-4192-B311-154B99800662Q30382548-A981CCB0-A6FE-4C76-8D0E-B4397AF2D36FQ30382809-0B125B27-B590-442C-A05E-069566FE8B05Q30398731-853247F3-3405-49EE-88D3-958FDE5A501DQ30421549-8B3064C0-DB8D-4274-AD4B-9178D2202531Q35125393-B99BA94B-EF32-4771-9D3D-65C5B1E0BE41Q35787563-630559E1-1C4E-4942-8EAF-C10900184AE8Q35886506-A9C60ED6-31A0-4EDA-9AF9-3388E4D88137Q36165344-0DC07211-8951-48A1-8AC3-26F194CB7C74Q36637886-A8433EBF-E02F-4879-BF31-6CB30C6BDE6AQ38061423-73E2D1FB-3689-4D91-8E4C-CD96BD59CA09Q40131850-E9B6B598-E816-4AF8-8000-1EFD33A1CA38Q40765131-9EFC862B-BA60-4768-9BE9-9BE84B310C20Q42696710-9463A96F-E885-4A2E-B4BE-126AC81AE1A6Q47262061-BE60239A-9C2C-4EE8-A585-A6E07365F468
P2860
Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Live attenuated pandemic influ ...... dness in developing countries.
@ast
Live attenuated pandemic influ ...... dness in developing countries.
@en
type
label
Live attenuated pandemic influ ...... dness in developing countries.
@ast
Live attenuated pandemic influ ...... dness in developing countries.
@en
prefLabel
Live attenuated pandemic influ ...... dness in developing countries.
@ast
Live attenuated pandemic influ ...... dness in developing countries.
@en
P2093
P50
P921
P1433
P1476
Live attenuated pandemic influ ...... edness in developing countries
@en
P2093
Alexander Mironov
Anatoly Naikhin
Dimitry Bushmenkov
Han van den Bosch
P356
10.1016/J.VACCINE.2011.04.122
P407
P478
29 Suppl 1
P577
2011-07-01T00:00:00Z